Table 2.

Phase III trials in relapsed and/or refractory MM: efficacy

Study (reference)RegimensPatients, nPrior therapies, median, n (range)Experimental vs placebo arm
ORR, %≥VGPR, %PFS, mo (HR)
Lenalidomide-based regimens
 ASPIRE (25)Rd ± carfilzomib7922 (1-3)87 vs 6770 vs 4026 vs 18 (0.69)
 TOURMALINE-MM1 (28)Rd ± ixazomib7221 (1-3)78 vs 7248 vs 3920.6 vs 14.7 (0.74)
 ELOQUENT 2 (27)Rd ± elotuzumab6462 (1-3)79 vs 6633 vs 2819.4 vs 14.9 (0.70)
 POLLUX (29)Rd ± daratumumab5691 (1-11)93 vs 7676 vs 44Not reached vs 18.4 (0.37)
Bortezomib-based regimens
 PANORAMA 1 (34)Vd ± panobinostat7681 (1-3)61 vs 55Not mentioned12 vs 8 (0.63)
 CASTOR (33)Vd ± daratumumab4982 (1->3)83 vs 6359 vs 29Not reached vs 7.16 (0.39)
 Randomized phase II study (35)Vd ± elotuzumab1501 (1-3)66 vs 6337 vs 279.7 vs 6.9 (0.72)
 ENDEAVOR (31)Kd vs Vd9291 (1-3)77 vs 6354 vs 2918.7 vs 9.4 (0.53)
  • ORR, overall response rate.